Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib.

Anti-cancer drugs - 1 Jan 2024

Li Qing, Xu Nengluan, Lin Ming, Chen Yusheng, Li Hongru

Abstract excerpt

Third-generation EGFR-TKIs can be used to treat advanced non-small cell lung cancer patients with T790M resistance mutation induced by first- or second-generation EGFR-TKIs. However, it will also result in drug resistance, and the resistance mechanisms of third-generation EGFR-TKIs are complex. Here we reported a patient diagnosed with advanced lung adenocarcinoma and EGFR positive in September 2016. Following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37449979
DOI: 10.1097/CAD.0000000000001530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib.PMID 37449979Read ↗

Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.Semantic proximity Read ↗

[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].Semantic proximity Read ↗

Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.Semantic proximity Read ↗

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.Semantic proximity Read ↗

Mechanism of afatinib resistance in non-small cell lung cancer patients with nonclassical EGFR mutations: A multicenter, retrospective study.Semantic proximity Read ↗

Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.Semantic proximity Read ↗

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.Semantic proximity Read ↗

[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)].Semantic proximity Read ↗

Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGSSemantic proximity Read ↗

Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 TrialSemantic proximity Read ↗

Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Semantic proximity Read ↗

Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.